DGAP-News

amp biosimilars announces Klaus K. Wilgenbus as new CEO - Seite 2

Klaus is an experienced biopharma executive and an outstanding dealmaker
whose skill-set will directly contribute to the firm's future growth path.
As a founder and shareholder I am excited about his future impact on the
company and will continue to support amp in any advisory or other capacity
required."

Chairman of amp Supervisory Board Dr. Thomas Zimmer comments: "With Klaus
Wilgenbus we have identified a leading pharma executive who brings a
tremendous wealth of pharma and biotech knowhow to amp biosimilars AG. The
addition of his business acumen enhances our ability to deliver high-value
biosimilars for the future. I thank Marc Hentz for his 2 years of
successful leadership in building the company and securing its first out
licensing deals, and I am sure that Klaus Wilgenbus will ensure the
continued expansion of our position as leader in biosimilar development."

About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand
on global therapeutic markets and is one of the most innovative and dynamic
biosimilar companies in Europe. The company is headquartered in Hamburg and
run by a team of leading industry experts. The development of a wide
variety of biosimilars will provide patients around the world with access
to life-improving and life-saving therapies. The combination of a research
platform with state-of-the-art analytics, process technology and clinical
expertise as well as regulatory know-how, makes amp biosimilars AG one of
the leading companies for biosimilar development and marketing. Thanks to
an international network of leading pharmaceutical companies, amp
biosimilars AG also has direct access to the strongest growing markets in
the world. With this approach amp biosimilars AG has a key position in one
of the fastest growing life science markets in the near future. amp
biosimilars AG has been listed on the Munich Stock Exchange since April 1,
2015. For more information please go to www.ampbiosimilars.com.

Contact:
Fabian Lorenz
Florenz Kommunikation
T: [phone]
E-mail: [e-mail]


---------------------------------------------------------------------------

28.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: amp biosimilars AG
Am Kaiserkai 1
22391 Hamburg
Germany
Phone: [phone]
Internet: http://www.ampbiosimilars.com
ISIN: DE000A0SMU87
WKN: A0SMU8
Listed: Regulated Unofficial Market in Munich


End of News DGAP News Service
---------------------------------------------------------------------------

474787 28.06.2016